Coronavirus disease 2019 (COVID-19) has developed into a pandemic and caused thousands of deaths worldwide. SARS CoV-2 infection can have a significant impact on cancer diagnosis, prognosis, and therapeutic effects. Some studies show a worse trend among cancer COVID-19 patients. However, other studies also indicate that the percentages of SARS-CoV-2 infection and severe events in cancer patients are not higher compared to the general population. It may be complicated in cancer patients, a high-risk group for SARS CoV-2 infection. The case study describe SARS CoV-2 infection in a 71-year-old male patient with neuroendocrine pancreatic cancer, who presented relatively mild illness without the need for intensive care. Complete recovery was achieved without short-term sequelae, and systemic oncological therapy was discontinued.
Polz-Dacewicz M, Stępień E, Dworzańska A, Malm M. COVID-19 in a patient with neuroendocrine pancreatic cancer. Case report. J Pre-Clin Clin Res. 2022; 16(1): 13–15. doi: 10.26444/jpccr/147709
Centers for Disease Control and Prevention. 2019 Novel coronavirus, Wuhan, China. Information for Healthcare Professionals. https://www. (access: 2021.09.08).
World Health Organization. Novel Coronavirus (2019-nCoV) technical guidance. (access:2021.09.05).
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndromerelated coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020; 5: 536.
Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8): 727–733.
Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13): 1239–1242. jama.2020.2648.
European Centre for Disease Prevention and Control. Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom, December 2020. https://www.ecdc.europa. eu/sites/default/files/documents/SARS-CoV-2-variant-multiple-spikeprotein-mutations-United-Kingdom.pdf (access:2020.12.21).
Wise J. Covid-19: New coronavirus variant is identified in UK. BMJ. 2020; 371: m4857.
Tang JW, Tambyah PA, Hui DS. Emergence of a new SARS-CoV-2 variant in the UK. J Infect. 2021; 82(4): e27-e28. jinf.2020.12.024.
Davies NG, Abbott S, Barnard CR, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021; 372(6538): eabg3055.
Desai A, Sachdeva S, Parekh T, et al. COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis. JCO Glob Oncol. 2020; 6: 557–559. https://
Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21:335–337.
Zhang J J, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020; 75(7):1730–1741.
Hallet J, Law CHL, Cukier M, et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015; 121: 589–597.
Wang B, Huang Y. Which type of cancer patients are more susceptible to the SARS-COX-2: Evidence from a meta-analysis and bioinformatics analysis. Crit Rev Oncol Hematol. 2020; 153: 103032. https://doi. org/10.1016/j.critrevonc.2020.103032.
Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020; 10(6): 783–791. CD-20-0422.
Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19- infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020; 31(7): 894–901. https://doi. org/10.1016/j.annonc.2020.03.296.
Yang F, Shi S, Zhu J, et al. Clinical characteristics and outcomes of cancer patients With COVID-19. J Med Virol. 2020; 92(10): 2067–2073.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497–506.
Marra A, Generali D, Zagami P, et al. Seroconversion in patients with cancer and oncology health care workers infected by SARS CoV-2. Ann Oncol. 2021; 32(1): 113–119.
Fazio N, Gervaso L, Halfdanarson TR, et al. Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study. Eur J Cancer. 2021; 154: 246–252. https://doi. org/10.1016/j.ejca.2021.06.029.